NuCana is a clinical-stage biopharmaceutical company focused on significantly improving survival outcomes for patients with cancer. We use our proprietary ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.
Our highly experienced management team has a successful track record of building global, integrated biopharmaceutical companies and bringing life-saving oncology therapeutics to patients.
"Utilising our proprietary ProTide technology platform we are developing new medicines designed to overcome key cancer resistance mechanisms and improve the survival outcomes for patients."
Our lead product candidate is designed to overcome the key cancer resistance mechanisms associated with gemcitabine. Currently in Phase I, II and III studies.
Our second ProTide is designed to overcome the key cancer resistance mechanisms associated with 5-FU. Currently in a Phase I study in patients with advanced solid tumours.
A ProTide transformation of cordycepin, a novel nucleoside analog with a unique mode of action and potent anti-cancer activity in preclinical studies. Initiating a Phase I study in 2018.
NuCana's ProTide technology is a powerful platform generating new anti-cancer medicines designed to overcome the key cancer resistance mechanisms.
We take a scientifically driven approach to designing our ProTides to address some of the most significant unmet medical needs in oncology.
NuCana announces first patients dosed in both US and Europe in Phase III Study of Acelarin (NUC-1031) for the first-line treatment of patients with Biliary Tract Cancer.
NuCana to Present at the Cowen and Company 40th Annual Health Care Conference
Tuesday, Mar 3, 2020